Role of adverse effects of immuno-allergic nature at a Regional Pharmacovigilance Center
Sorbette, F.; Conte, S.; Montastruc, J.L.
Therapie 47(5): 445-446
1992
ISSN/ISBN: 0040-5957 PMID: 1299998 Document Number: 403922
Document emailed within 1 workday
Related Documents
Bruneau, S.; Bruhat, C.; Lagarce, L.; Lainé-Cessac, P. 2001: Retrospective study of adverse drug reactions in the elderly: experience of regional center for pharmacovigilance Therapie 56(6): 785-791Jaźwińska-Tarnawska, E.; Wiela-Hojeńska, A.; Wolańczyk-Medrala, A.; Patkowski, J.; Nittner-Marszalska, M.; Głowacka, K. 2012: Monitoring of NSAIDs adverse effects based on spontaneous reports from Wrocław regional adverse drug reactions monitoring center Acta Poloniae Pharmaceutica 69(5): 979-984
Bidault, I.; Maignen, F.; Estrache, M.; Castot, A. 1993: Risks related to the resorption of a glycine-based irrigation solution. 10 cases reported to the Poison Control Center and the Regional Center of Pharmacovigilance of Paris-Fernand-Widal Therapie 48(5): 498-499
Labadie, J.; van Grootheest, A.C. 2007: Adverse events following vaccination reported to the Netherlands Pharmacovigilance Center Lareb in 2004-2006 Nederlands tijdschrift voor geneeskunde 151(49): 2738-2742
Veyrac, G.; Marcade, G.; Chiffoleau, A.; Bourin, M.; Jolliet, P. 2002: Characteristics of hypersensitivity syndrome to lamotrigine: review of one case reported in the Regional Center of Pharmacovigilance of Nantes Therapie 57(3): 289-296
Jacquet, A.; Sorbette, F.; Montastruc, J.L. 1993: Evaluation of ten years of pharmacovigilance of antihypertensive drugs in the Toulouse University Regional Hospital Center (1981-1990) Therapie 48(2): 141-144
Wongratanacheewin, S. 2013: Molecular nature and the phylogenetic of allergic pollens play role in allergic diseases Asian Pacific Journal of Allergy and Immunology 31(4): 259
Teregeria, N.I. 1975: Case of regional ileitis of allergic nature Klinicheskaia Khirurgiia 7: 71
Jean-Pastor, M.J.; Morange-Sala, S.; Rodor, F.; Gambini, D.; Galland, M.C.; David, J.M.; Jouglard, J. 1992: Role of pharmacovigilance center in information for the public on drugs. Experience in Marseille on 9 month Therapie 47(5): 429-432
Prosvetov, I.V.; Spesivtsev, O.G.; Gal'chanskaia, L.D. 1990: A decline in the efficacy of hyposensitization due to the adverse effects of antitubercular agents against a background of immuno-correction Problemy Tuberkuleza 1990(11): 54-55
Kaaber, K.; Menne, T.; Veien, N.K.; Baadsgaard, O. 1987: Some adverse effects of disulfiram in the treatment of nickel-allergic patients Dermatosen in Beruf und Umwelt. Occupation and Environment 35(6): 209-211
Głośnicka, R. 2001: The role and goals of the Regional Center "Salmonella" Przeglad Epidemiologiczny 55(1 Suppl 2: 13-18
Richter, G. 1975: Critical evaluation of external dermatologic agents under the aspect of their allergic adverse effects Dermatologische Monatschrift 161(5): 384-387
Gottwald, W. 1970: Adverse effects of drugs in tuberculous patients. Allergic reactions due to isoniazid and hydantoins or disulfiram Medizinische Monatsschrift 24(3): 111-115
Udagawa, K. 2003: Role of disabled children's school as regional special education center No to Hattatsu 35(3): 223-227
Kalaiselvan, V.; Prasad, T.; Bisht, A.; Singh, S.; Singh, G.Nath. 2014: Adverse drug reactions reporting culture in Pharmacovigilance Programme of India Indian Journal of Medical Research 140(4): 563-564
Yang, W.; Xiang, Y.-Y.; Xie, Y.-M.; Shen, H. 2013: Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening Zhongguo Zhong Yao Za Zhi 38(18): 3013-3018
Bukirwa, H.; Nayiga, S.; Lubanga, R.; Mwebaza, N.; Chandler, C.; Hopkins, H.; Talisuna, A.O.; Staedke, S.G. 2008: Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events Tropical Medicine and International Health: Tm and Ih 13(9): 1143-1152
Albin, H.; Begaud, B.; Haramburu, F.; Père, J.C.; Dangoumau, J. 1982: Blood dyscrasias and imputability. Observations from the Bordeaux-Aquitaine Pharmacovigilance Center Therapie 37(4): 409-414
Thomas, R.E.; Lorenzetti, D.L.; Spragins, W.; Jackson, D.; Williamson, T. 2011: Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review Current Drug Safety 6(3): 145-154